Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal
Firm Signs Commercialization and License Agreement With Bio-Thera Solutions
Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.
